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Abstract
Focusing on the study of human memory CLA+ T cells to understand psoriasis pathology 
constitutes an innovative approach to explore the pathological mechanism of this chronic 
cutaneous inflammatory disease. CLA+ T cells can be considered peripheral cell bio-
markers in the study of T-cell mediated human skin diseases. During the last few years, 
new evidences have been found that link streptococcal infection with IL-17 response in 
psoriasis by studying the interaction between Streptococcus pyogenes with CLA+ T cells 
and autologous epidermal cells. S. pyogenes constitutes the best clinically characterized 
trigger of psoriasis and by exploring its effect on CLA+ T cells and epidermal cells in 
psoriasis may allow understanding psoriasis by using patient’s clinical samples ex vivo.
Keywords: psoriasis, CLA+ T cells, translational research, Streptococcus pyogenes, IL17
1. CLA+ T cells and the regional cutaneous immune system
The adaptive immune responses taking place during cutaneous chronic inflammation in pso-
riasis preferentially involve a subset of memory T lymphocytes, which are related to the skin 
and that belong to the cutaneous immune system, and constitute one of the best character-
ized regional immune systems of the body and known for decades [1]. In the humans, the 
cutaneous lymphocyte-associated antigen (CLA) is a surface cell marker that allows identify-
ing T cells that belong to the cutaneous immune system. The CLA antigen is a carbohydrate 
expressed by 15% of human circulating T cells, and on most (>90%) skin-infiltrating T cells, 
contrary to other inflamed organs [2]. CLA is expressed preferentially on memory antigen-
experienced T cells.
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The CLA is one of the adhesion molecule that, together with chemokine receptors, allows T 
cells to selectively migrate to the skin, in either homeostatic or inflammatory conditions, by 
binding to endothelial cell wall via adhesion molecules or ligands. The molecular interactions 
between CLA/E-selectin, very late antigen-4 (VLA-4)/vascular cell adhesion  protein-1 (VCAM-1), 
lymphocyte function-associated antigen-1 (LFA-1)/intercellular adhesion  molecule-1 (ICAM-1), 
and chemokine ligands for chemokine, C-C motif receptor (CCR) 10, CCR4, CCR6, and CCR8 
constitute a code bar system enabling skin infiltration [3].
The importance of circulating CLA+ T cells for understanding the skin immune system is not 
only based on their capacity to selectively migrate to skin, but also on the fact that these cir-
culating memory T cells are functionally related to the immune response taking place in the 
cutaneous inflamed lesions. This feature is based on the recirculating capacity of those cells 
between lesional skin and blood during cutaneous inflammation in psoriasis [3]. The adhesive 
interaction between LFA-1 and ICAM-1 is one of the mechanisms involved in the transendo-
thelial migration of CLA+ T cells [4]. Interestingly, the blockade of LFA-1/ICAM-1 interaction 
in psoriasis patients with anti-LFA-1 in patients blocks extravasation and leads to CLA+ T cell 
lymphocytosis. Such accumulation of CLA+ T cells in the blood has clinical relevance since 
skin relapse may develop after stopping the anti-LFA-1 treatment [3].
The function and phenotype of circulating CLA+ T cells in T-cell mediated skin disease have 
been studied in many different human skin conditions. Those skin-seeking memory T cells 
respond to antigens, allergens, or superantigens that play a key role in disease triggering of 
different human T-cell mediated skin diseases, see Table 1. In addition, their phenotype and 
function are related to clinical status of the patient. For these reasons, those cells are consid-
ered peripheral cell biomarkers of T-cell mediated human cutaneous diseases [3, 5, 6].
2. Translational research and clinically relevant pathological mechanism 
of psoriasis
The innovation in psoriasis treatment has benefited from the continuous bidirectional flow of 
information from the bedside of clinic to the laboratory and vice versa [7]. Innovative patho-
genic concepts have been tested in patients through the use of targeted therapeutics  leading to 
Disease Antigen involved in disease triggering
Atopic dermatitis House dust mite [59]
Casein [60]
TCRVβ for SEB [61]
Contact dermatitis Nickel [59]
Drug-induced allergic reaction Betalactams [62]
Herpex simplex HSV-2 [63]
Vitiligo Melan-A [64]
Table 1. Selective response of circulating CLA+ T cells to antigens involved in cutaneous disease triggering.
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clinically validated mechanism of disease. Those mechanisms that started as a merely scientific 
hypothesis of disease that can be proven to be relevant in the clinic by specific biological treat-
ments allow improvement in the therapeutic arsenal for patients. At present, it is possible to 
understand psoriasis from several of its clinically relevant mechanism/targets that has been 
validated in the clinic since that has provided clinical benefit in patient. The current clinically 
validated concept of psoriasis is summarized in Tables 2 and 3. During the last two decades 
approximately, it has been demonstrated the key role of the IL-23/Th17 axis in psoriasis [8]. The 
journey to the current situation in psoriasis treatment started by evidencing that T-cell activity 
in psoriasis had real implications for the patients. Thus, depletion of T cells [9, 10], costimula-
tion [11], and inhibition of their migration from blood to skin demonstrated improvement in 
the clinical severity [12]. Not only memory T cells are of translational relevance in psoriasis, but 
also TNF-α is a key cytokine for this disease. Although originally thought not to be associated to 
T-cell function, lately it was demonstrated that TNF-α neutralization affects Th17 function [13]. 
The introduction of ustekinumab, a monoclonal antibody that neutralizes both IL-12 and IL-23, 
cytokines involved in differentiation of Th1 and Th17 cells, respectively, marked the initiation 
of the IL-23/Th17 axis era [14]. In contrast to the increased amounts of IL-23, there is no marked 
increase of IL-12 in psoriatic lesion in comparison to nonlesional or healthy [15]. It became evi-
dent that the ustekinumab clinical efficacy was related to inhibition of the IL-23 biological effect.
The next step was to translate the consequence of blocking the IL-23, a cytokine involved in 
the differentiation of T cells producing IL-17, into the clinic. The selective inhibition of the 
biological activity of IL-17A, or its receptor IL-17RA, has demonstrated an impressive clinical 
efficacy in patients in the clinical trials. The most innovative approach currently is to block 
Biological treatment Mechanism action Target Relevance
DAB389-IL-2 Toxin acting on cells expressing 
IL-2 receptor
CD25 T-cells are important in psoriasis [9]
CTLA4-Ig T cell costimulation blockade CD80, CD86 Blocking T cell activation improve 
psoriasis [11]
LFA-3-Ig Memory T cell depletion CD2 Memory T cells are relevant in 
psoriasis [10]
Anti-LFA-1 T cell migration and T-cell 
costimulation inhibitor
LFA-1 Migration of T cells to psoriasis lesion 
is involved in disease [12]
Anti-TNF-α Neutralization of biological 
activity
TNF-α Biological activity of TNF-α is 
involved in psoriasis [65]
Anti-p40
(IL-12/ IL-23)




Cytokines involved in generating Th1 
and Th17 are relevant in psoriasis [14]
Anti-IL-17A Neutralization of I biological 
activity
IL-17A Other cytokines besides TNF play a 
role in psoriasis [66]
Anti-IL-17RA Blockade of receptor IL-17RA IL-17 signaling plays a relevant role in 
psoriasis [67]
Anti-IL-23p19 Neutralization of biological 
activity
IL-23p19 IL-23/Th17 axis play essential role in 
psoriasis [16]
Table 2. Targeted therapeutics that have evidenced clinically relevant mechanisms of psoriasis.
Human Translational Research in Psoriasis Using CLA+ T Cells
http://dx.doi.org/10.5772/67815
63
selectively IL-23, which also has confirmed the clinical relevance of specifically blocking the 
IL-23/Th17 in psoriasis [16].
In contrast to the mediators or cells that have confirmed its relevance in psoriasis due to its 
clinical importance in reducing disease severity, there are several well-known mechanisms 
present in psoriasis that have not been validated in the clinic, since their biological neutraliza-
tion in the patient has not brought clinical benefit, see Table 3. Mediators such us IFN-γ, IFN-α, 
IL-8, and IL-22 have been neutralized in patients without significant clinical improvement.
When studying psoriasis triggering factors from the translational point of view, perhaps the 
best characterized environmental factor is throat infection by β-hemolytic streptococci. As it 
is commented below, there is a great body of evidences that associate streptococcal infection 
with psoriasis flares or exacerbations in both guttate and plaque psoriasis. This can be consid-
ered a translational opportunity of studying psoriasis immune response from a different and 
innovative perspective.
3. Streptococcal pyogenes infection and psoriasis
Throat infection by β-hemolytic streptococci has been associated with both the flare and exac-
erbation of psoriasis [17–19]. In guttate psoriasis, this infection precedes clinical cutaneous 
symptoms in 56–97% of the cases [20]. Interestingly, chronic plaque psoriasis patients are 
more susceptible to throat infections by Streptococcus pyogenes (Sp) than healthy controls [19], 
present increased levels of IgG for S. pyogenes in comparison to healthy controls [21], and a 
substantial proportion of patients suffer from disease exacerbations by streptococcal throat 
infections [22]. The association of S. pyogenes infection and psoriasis, besides being clinically 
evidenced for many years, may also open opportunities to treat psoriasis since several studies 
have shown that tonsillectomy can bring clinical benefits [23–26] and also improvement in the 
quality of life of the patients [26].
An immunological model has been proposed to explain how an infection taking place in the 
throat can lead to a chronic inflammation in a distant tissue such as the skin. One interesting 
observation is to note that dendritic cells from tonsils and upper respiratory truck are capable of 
Biological treatment Mechanism of action Target Relevance
IL-8 Neutralization of biological 
activity
IL-8 IL-8 is not clinically validated in 
psoriasis [68]
IFN-γ Neutralization of biological 
activity
IFN-γ IFN-γ is not clinically validated in 
psoriasis [69]
IFN-α Neutralization of biological 
activity
IFN-α IFN-α is not clinically validated in 
psoriasis [70]
IL-22 Neutralization of biological 
activity
IL-22 IL-22 is not clinically validated in 
psoriasis [71]
Table 3. Lack of efficacy by targeted therapeutics evidenced nonclinically validated mechanisms of psoriasis.
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generating some skin-tropic CLA+ T cells [27], thus indicating that those cells can acquire anti-
gen-specificity for microbes infecting noncutaneous sites. In this regard, streptococcal superan-
tigens promote the expression of CLA on T cells [28], as well as the activation and expansion of 
CLA+ T cells, at least from guttate psoriasis. Guttate psoriasis is an acute form of psoriasis, which 
erupts as small drop-shaped papules, and is frequently associated with streptococcal throat 
infection. In particular, accumulation of Vβ2+ T cells in acute guttate lesions has been reported, a variable β chain expressed on T cells that are preferentially expanded through the streptococcal 
pyrogenic exotoxin (SPE)-C [29], which contained T cells with different junctional sequences in 
the CDR3 region, thus supporting a superantigen-driven expansion. However, as psoriasis pro-
gresses, such superantigen hypothesis does not seem to explain the presence of identical TCR 
rearrangements in plaque psoriasis patients, probably indicating that a stable antigen-specific 
T-cell response is involved for longer stages of the disease [30, 31]. Interestingly, T-cell lines 
isolated from psoriatic lesions have shown strong cross-reactivity to streptococcal antigens [32]. 
Furthermore, restricted TCRVβ spectratypes shared by CLA+ T cells in streptococcal angina, but 
not by CLA− T cells, with T cells in psoriasis skin lesions supports the idea of the existence of a 
tonsillar source of antigen-driven T-cell expansion that then migrate to the skin [33]. Altogether, 
streptococcal superantigens could facilitate at least early migration of tonsillar T cells to the skin 
by upregulating CLA expression and could be especially involved in guttate-type flares.
S. pyogenes-primed T cells that reach the skin under postinfection circumstances are, however, 
unlikely to be maintained by the intracutaneous presence of streptococcal antigens in the skin 
for long periods of time. Therefore, other antigens would be responsible for the activation of 
those T cells. The hypothesis of molecular mimicry between streptococcal and skin peptides 
has been proposed by some authors. This view supports that CD8+ T cells could be cross-
reacting to auto-epitopes presented through the context of MHC-I molecules on the surface of 
activated keratinocytes or cross-presenting dendritic cells [32, 34]. Actually, common determi-
nants have been identified between streptococcal M-protein and skin keratins. Interestingly, 
the expression of M-protein is only associated with the three groups of β-hemolytic strepto-
cocci (A, C and G) that more often cause throat infections that precede the onset or exacerba-
tions of psoriasis lesions [19]. In fact, circulating CLA+ T cells that cross-react with M-protein 
and human keratin 17, which is upregulated in psoriatic lesions, decrease after tonsillectomy 
and correlate with clinical improvement [35].
Despite the evidence of streptococcal involvement in psoriasis course, the use of antibiotics 
has not proven effectiveness in psoriasis [36]. However, it might be explained by the fact that 
streptococci can exist in intracellular reservoirs in the tonsillar epithelia and macrophages, 
and that could not be affected by the use of antibiotics. Then, this quiescent load could be 
reactivated and cause disease symptoms again, whereas tonsillectomy, which has been asso-
ciated to clinical improvement, might remove this hidden pool of streptococci [22, 37].
Other entry routes for S. pyogenes can be considered, such as through the skin barrier itself, and 
could play a role as instigators of psoriasis disease. In fact, it has been detected in the skin but 
not in the throats of some guttate psoriasis patients [38]. Such presence, although transitory, 
might be enough to generate an antibacterial immune response that could lead to autoimmune 
reactions against local skin-derived peptides [39]. Overall, there is a strong relationship between 
streptococcal infections and subsequent clinical events in psoriasis that needs further attention.
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4. Streptococcus pyogenes: an innate trigger that induces IL-17 production 
through skin-related memory CLA+ T cells in psoriasis
Analyzing the antigen-specific immune responses with clinically relevant stimuli in respond-
ing patients allows identifying pathologic translational mechanisms of several immuno-
logic diseases, including psoriasis. This experimental approach can be reproduced ex vivo 
by coculturing circulating memory CLA+ T cells together with autologous epidermal cells 
from psoriasis patients and are activated by the S. pyogenes extract [40]. In this study, it 
was demonstrated that in psoriasis S. pyogenes preferentially activates cocultures of CLA+ T 
cells and epidermal cells, but not with CLA− T cells from the same patient, nor in cultures 
using CLA+/CLA− cells from healthy controls. The activation of CLA+ T cells showed at the 
transcript and protein level a response to the S. pyogenes extract with a mixed Th17/Th1/
Th22 profile, since IL-17A, IFN-γ, and IL-22 were already upregulated in the coculture at 24 
hours after activation and secreted as early as 48 hours. The CLA-dependent immune reac-
tion in the coculture also included several other psoriasis-associated mediators such as the 
immune cell-chemoattractants CXCL8 (also known as IL-8), CXCL9, CXCL10, and CXCL11, 
which are expressed in psoriasis lesions [41], and when such enriched media were intra-
dermally injected in mice, an epidermal hyperplasia was found. Furthermore, the presence 
of epidermal cells in the ex vivo model seems crucial for cytokine production through the 
activation with S. pyogenes, proving an intercellular interaction which may imply both CD4+ 
and CD8+ T cells. This conclusion was based on the observation that cytokine levels were 
highly impaired after blocking HLA class I and class II molecules. Interestingly, if circulating 
CLA+ T cells were cocultured with nonlesional epidermal cells, levels of several inflamma-
tory mediators were upregulated when cells were activated with S. pyogenes, thus supporting 
the initial role of CLA+ T cells in driving nonlesional skin to the plaque formation [42, 43]. 
Overall, this novel model provided first evidence of a direct implication of CLA+ T cells and 
S. pyogenes in psoriasis samples treated ex vivo, while no such response was reproduced with 
healthy samples. These first results shed new light on the study of psoriasis, providing a tool 
for further valuable translational studies.
Since the closest and clearest relationship between streptococcal infection and subsequent 
onset of lesions has been described for guttate-type psoriasis, the evaluation of immune 
responses in the context of S. pyogenes-activation of key cellular components of psoriasis 
lesions from guttate psoriasis patients may generate more faithful results regarding the clini-
cal status of such patients. Moreover, guttate psoriasis represents an important form of pso-
riasis since it contributes to its natural history. Actually, almost 40% of guttate psoriasis cases 
develop chronic plaque psoriasis in the future, and guttate-type eruptions are seen in plaque-
affected patients [44]. Therefore, early events of psoriasis development can be studied in gut-
tate psoriasis under the abovementioned microbial trigger [45].
A second study based on this ex vivo model focused on guttate psoriasis and revealed the 
importance of the Th17 immune response over other T cell-dependent responses, such as Th1, 
since IL-17A and IL-17F levels produced by CLA+ T cells in the cocultures in the presence of 
S. pyogenes extract were significantly higher than those of IFN-γ [46].
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The importance of Th17 role in initial steps of psoriasis development is also supported by other 
findings, such as the high levels in serum of IL-17 found in patients with early spreading guttate 
form [47]. Even a bimodal immunopathology theory proposes that psoriasis is initiated by IL-1/
Th17-dominated responses [48]. In addition to the well-known association of preceding phar-
yngitis episode, guttate psoriasis onset is mostly confined to individuals carrying the HLA-Cw6 
allele [49], a genetic risk factor for early psoriasis. Interestingly, when immune responses from 
guttate psoriasis samples were classified according with the simultaneous presence of both 
genetic and environmental factors, that is HLA-Cw6 allele and a prior pharyngitis episode, 
respectively, the Th17-associated response was higher than that exerted by samples from the 
other “nonpredisposed” guttate psoriatic individuals. In fact, significant higher levels of IL-17A, 
IL-17F, and even IL-6, which participates in Th17-differentiation, were found in those “predis-
posed” guttate psoriasis patients. Furthermore, the treatment of in vitro cultured normal kerati-
nocytes with those Th17-predominant supernatants produced by CLA+ T cells in the cocultures, 
resulted in the upregulation of the IL-17-targeted transcripts DEFB4, S100A7, LCN2, IL36G, and 
IL8, which are all overexpressed in psoriasis lesions [50]. Interestingly, filaggrin and loricrin, 
encoded by FLG and LOR genes, respectively, which are important skin barrier proteins whose 
expression is impaired in psoriatic lesions [51, 52], were downregulated in those same treated 
keratinocytes. Therefore, S. pyogenes selective-activation of CLA+ T cells in the presence of epi-
dermal cells from high-responders guttate psoriasis samples recreates a psoriasis-like inflam-
matory milieu, thus supporting the high translational value of this ex vivo model.
Therapies targeting the IL-23/Th17-axis are showing the best efficacy rates in terms of per-
centage of patients reaching PASI improvement. The observation of rapid normalization of 
hundreds of psoriasis-related genes as soon as 2 weeks after the use of IL-17A or IL-17RA-
blocking antibodies [53, 54] may partly explain the importance of IL-17A effects in psoriasis 
pathology, and why its blockade provides such impressive clinical improvement. Therefore, 
the characterization of IL-17-targeted transcripts that are rapidly normalized after these thera-
pies could reveal relevant information regarding to the development of skin lesions.
In this regard, Ruiz-Romeu et al. [55] have taken advantage of the use of CLA+ T cell and epi-
dermal cells activated by SE conditioned supernatants to activate normal keratinocytes and to 
evaluate gene expression of noncharacterized IL-17A targets. In their study, they character-
ize the expression of ZC3H12A, a gene whose rapid normalization was found in gene arrays 
of biopsies taken from psoriasis patients treated with the anti-IL-17A monoclonal antibody 
[53]. ZC3H12A encodes for the ribonuclease MCPIP1, and it was upregulated in keratinocytes 
treated with enriched supernatants in an IL-17A-dependent manner. The fact that lack of 
upregulation in Zc3h12a expression in the skin of an innate psoriasis model induced in Il17ra−/− 
mice supports the key dependence on IL-17 for its increased expression in psoriasis. MCPIP1 
activity has been linked to many different biological processes within various cell types, such 
as inhibition of inflammation, angiogenesis, cell migration, or cell differentiation [56], but 
no prior evidence of MCPIP1 expression and function in the skin had been reported. In this 
study, MCPIP1 expression was found to be aberrantly expressed by suprabasal keratinocytes 
of psoriasis lesions, which is consistent with the distribution of that described for IL-17RA in 
the psoriatic epidermis [57, 58]. In this regard, only differentiating keratinocytes isolated from 
psoriatic lesional skin, but not from healthy skin, were susceptible to undergo an increased 
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expression of MCPIP1 to exogenous IL-17A. Regarding to the potential role of MCPIP1 ribo-
nuclease activity, genes involved in epidermal differentiation, or other altered transcripts in 
psoriasis lesions, are modified after a ZC3H12A knockdown in keratinocytes.
5. Conclusions
The translational approach of developing an ex vivo model using peripheral CLA+ T cells 
and epidermal cells, activated by a clinically relevant innate trigger, such as S. pyogenes, can 
be useful in the characterization of immune responses and new molecular mechanisms that 
could be involved in the psoriasis pathogenesis.
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